[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592532":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":52,"collaborators":11,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HRS9531","EXPERIMENTAL",null,[13],"Drug: HRS9531",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","HRS9531 will be administered by Subcutaneous injection",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Matching Placebo will be administered by Subcutaneous injection",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Siai Sun","CONTACT","18036618062","siai.sun@hengrui.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Peking University People's Hospital","RECRUITING","Beijing","Beijing Municipality","100044","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49],{"name":50,"role":51,"phone":11,"phoneExt":11,"email":11},"Fang Han","PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100592532","phase-3-a-multicenter-randomized-double-blind-placebo-controlled-phase-iii-clinical-study-to-evaluate-the-efficacy-and-safety-of-hrs9531-injection-in-subjects-with-obstructive-sleep-apnea-osa-and-obesity-who-are-on-positive-airway-pressure-ventilation-pap-therapy-100592532",false,"NCT06994650","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy","Inclusion Criteria:\n\n1. Aged 18 -75 (inclusive), male or female Sex\n2. BMI ≥28.0 kg\u002Fm2；\n3. ≥3 months of diet\u002Fexercise control pre-screening with ≤5.0 kg weight fluctuation in prior 3 months.\n4. Confirmed OSA diagnosis with screening PSG showing AHI ≥15.0 events\u002Fh.\n5. ≥3 months of PAP therapy pre-screening with planned continuation; willingness to pause PAP ≥1 week before each PSG.\n6. Females\u002Fmales of childbearing potential must use highly effective contraception from consent until 2 months post-treatment, with no pregnancy\u002Fdonation plans. Females require negative pregnancy test ≤3 days pre-randomization and non-lactating.\n\nExclusion Criteria:\n\n1. Endocrine disorders significantly affecting weight (e.g., Cushing's syndrome, hypo-\u002Fhyperthyroidism) or monogenic\u002Fhereditary obesity syndromes excluded.\n2. Diabetes mellitus (excluding gestational diabetes).\n3. Prior\u002Fplanned OSA-related major surgeries (e.g., tonsillectomy\u002Fadenoidectomy) that may affect breathing.\n4. Have significant craniofacial abnormalities that may affect breathing at baseline\n5. Have diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas\u002Fhypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration\n6. Respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator.\n7. Impaired gastric emptying (e.g., gastric bypass, pyloric stenosis)；Chronic use of GI motility-affecting drugs；Severe GI disorders (e.g., active PUD, IBD)；GI surgeries (except non-motility-affecting procedures)\n8. Pancreatic disorders (acute\u002Fchronic pancreatitis, pancreatic injury)；Acute cholecystitis history；Symptomatic\u002Ftreated gallbladder disease\n9. Have used drugs or treatments that may cause significant weight gain or loss within 3 months\n10. Investigator-determined unsuitability\u002Funwillingness to pause PAP therapy for at least 1 week pre-PSG (e.g., safety\u002Foccupational\u002Fpersonal considerations).","ALL","18 Years","75 Years",{"count":64,"type":65},140,"ESTIMATED","INTERVENTIONAL",[68],"PHASE3","This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.",[71],"Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy","2026-01-22",{"date":74,"type":75},"2026-01-26","ACTUAL",{"date":77,"type":75},"2025-08-13",{"date":79,"type":65},"2027-01",{"name":5,"class":6},1]